NCT00698685 · FLOW

Participant flow

Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation · Source last updated 2017-03-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic \[related or unrelated\] Hematopoietic SCT. Pentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.
id
FG000
title
Preparative Regimen of Pentostatin and Alemtuzumab

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
1
type
Sister withdrew as donor
reasons
group Id
FG000
num Subjects
1
type
Off study pre transplant by clinic MD
milestones
achievements
group Id
FG000
num Subjects
14
type
STARTED
achievements
group Id
FG000
num Subjects
12
type
COMPLETED
achievements
group Id
FG000
num Subjects
2
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

Following consent process, subjects who consented to participate were screened per the selection criteria in the study.

recruitment Details

Following University of Arizona IRB review and approval, the study opened to accrual on November 2005 at the Arizona Cancer Center clinic and University Medical Center sites \[Tucson, Arizona\].

Complete source fields